Novo Nordisk A/S Common Stock (NVO)

With water scarcity, AI acceleration, and GLP-1 drugs reshaping demand, deal professionals are sprinting to adapt.

Hedge funds shorting Hims & Hers Health Inc (NYSE:HIMS) may regret it - earnings with a positive surprise could lead to a short squeeze as stock continues to rise, up 96% in past month.

Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.

NOVO-NORDISK A/S-SPONS ADR could be undervalued. NYSE:NVO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.

This isn't just any growth stock.

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its injectables.

Buying Novo Nordisk stock looks like the cheapest way to invest in GLP-1 drugs.

Sales of Novo Nordisk’s flagship weight loss drug Wegovy surged 85% in the first quarter of the fiscal year 2025, while its diabetes treatment Ozempic posted an 18% increase.

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid GLP-1 competition.

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 view.

Hims & Hers is on fire right now.

Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments.

Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now staring at a bankruptcy process to reorganize its finances.

Good news for Hims & Hers stock spooks Lilly and Novo investors.

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

The company recently inked a deal with Novo Nordisk. But will that bolster current-quarter sales?

Hims stock rose Monday after the telehealth program named technology industry veteran Nader Kabbani as its new chief operating officer.

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to expand into other healthcare areas.